NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/02/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization704.8 mln
Float267 mln
Earnings Date10/29/2026
Piotroski F-Score
4
/ 9
Borderline
1-Year Forecast
9.00
Transformational upside
Relative Strength
11
/ 100
Significantly lagging
Debt / Equity
0.16
Very low leverage
ROE
-49.62
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Allogene Therapeutics is a clinical-stage biotechnology company focused on developing cancer and autoimmune disease treatments using off-the-shelf T cell therapies derived from donor cells rather than a patient's own. Founded in 2017 and based in South San Francisco, the company is advancing several treatment candidates, including therapies targeting blood cancers, kidney cancer, and conditions such as lupus. Its lead programs include cema-cel for large B-cell lymphoma and ALLO-329, which addresses multiple autoimmune diseases by targeting two proteins simultaneously.
